# An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

> **NCT00403767** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 14269 (actual)

## Conditions studied

- Atrial Fibrillation
- Stroke
- Embolism

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Warfarin
- **DRUG:** Matching placebo for Rivaroxaban arm (Warfarin placebo)
- **DRUG:** Matching placebo for Warfarin arm (Rivaroxaban placebo)

## Key facts

- **NCT ID:** NCT00403767
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 14269 (ACTUAL)
- **Last updated:** 2014-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403767, "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00403767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*